Global Tuberculosis Vaccine Treatment Market Insights and Forecast to 2027

SKU ID : QYR-18135372 | Publishing Date : 28-Apr-2021 | No. of pages : 117

Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.

Besides, BCG Vaccine is also used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.
In the last several years, global market of Tuberculosis Vaccine Treatment developed smoothly, with an average growth rate of 0.73%.
The classification of Tuberculosis Vaccine Treatment includes Immune Vaccine and Therapy Vaccine, and the proportion of Immune Vaccine in 2019 is about 99.66%.
Tuberculosis Vaccine Treatment is widely sold through Self-Procurement, UNICEF and Other. The most proportion of Tuberculosis Vaccine Treatment is sold through Self-Procurement, and the proportion in 2019 is 62.14%.
Asia-Pacific is the largest consumption place, with a consumption market share nearly 45% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of 35.66%.
Market competition is intense. Merck, Japan BCG Lab, Serum Institute of India are the leaders of the industry, they occupy the 60% of the market.

Market Analysis and Insights: Global Tuberculosis Vaccine Treatment Market
The global Tuberculosis Vaccine Treatment market is valued at US$ 70 million in 2019. The market size will reach US$ 85 million by the end of 2026, growing at a CAGR of 2.9% during 2021-2026.

Global Tuberculosis Vaccine Treatment Scope and Market Size
Tuberculosis Vaccine Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Tuberculosis Vaccine Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
Immune Vaccine
Therapy Vaccine

Segment by Application
Self-Procurement
UNICEF
Other

By Company
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC
Queen Saovabha Mem. Inst
Microgen

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia

Frequently Asked Questions

This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
  • By product type
  • By End User/Applications
  • By Technology
  • By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
market Reports market Reports